- Home
- GALT vs GNLX Comparison
GALT vs GNLX Comparison
Compare GALT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | GNLX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.3M | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GALT | GNLX |
|---|---|---|
| Price | $6.13 | $4.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.00 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 440.3K | 194.5K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.99 |
| 52 Week High | $6.66 | $8.54 |
Technical Indicators
Market Signals| Indicator | GALT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 34.52 |
| Support Level | $5.10 | $4.37 |
| Resistance Level | $6.32 | $4.75 |
| Average True Range (ATR) | 0.52 | 0.42 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 66.03 | 3.19 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.